INTRODUCTION
effectively inhibits tumor-and ocular-angiogenesis and also reduces vascular leakage (9, (12) (13) (14) .
However, VEGF-Trap targets only VEGF-Arelated diseases. Tumor necrosis factor-alpha (TNF-α) mediates the immune response by recruiting leukocyte to the site of inflammation (15) . TNF-α is an important molecule in the initiation of inflammatory responses through activation of NF-κB in the inflammatory cells including macrophages, endothelial cells, and dendritic cells (16, 17) . Several approaches have been developed to block TNF-α action. For instance, Amgen Inc. developed a TNF-α decoy receptor, Enbrel, which is currently being used to treat many inflammatory diseases related to TNF-α (18, 19) . Human VEGFR1 is separated by three major regions: an extracellular domain consisting of seven immunoglobulin (Ig)-like domains, a transmembrane domain, and an intracellular tyrosine kinase domain (20, 21) . The Ig-like domain 2 among seven Ig-like domain in VEGFR1 is essential for VEGF-A binding (20, 21) .
However, the Ig-like domain 2 of VEGFR1 contains many basic amino acids and its theoretical isoelectric point (pI) is 9.19 (9, 20) . In general, positively charged, high value of pI proteins bind non-specifically to the extracellular matrix that is negatively charged (22) . Therefore, the Ig-like domain 2 of VEGFR1 per se might not be used as a therapeutic protein due to its poor pharmacokinetic properties (9) . Human TNFR2 is separated by three major regions: an extracellular domain consisting of four cysteine-rich domains, a transmembrane domain, and an intracellular domain (23, 24) . The four cysteine-rich domains of extracellular domain of TNFR2 are essential for TNF binding (23, 25) . Although this subdomain contains many basic amino acids, theoretical isoelectric point (pI) of this subdomain is 6.5 because it possesses high amounts of cysteine and other acidic amino acids.
The underlying causes of vision loss in blinding retinal diseases, such as proliferative diabetic retinopathy and age-related macular degeneration, are abnormal and excessive neovascularization and increased vascular permeability (7, 26, 27) . shown to recapitulate many pathological and molecular hallmarks of human psoriasis (31, 33, 34) .
Rheumatoid arthritis (RA) is a disabling disease that can cause bone destruction and permanent deformity (6, 35) . The hallmark of RA is synovial cell proliferation in response to inflammatory stimuli, leading to the formation of the rheumatoid pannus (6, 35) . One of the earliest events observed in synovitis is the development of new vessels in the synovium, and VEGF-A is strongly expressed by subsynovial macrophages, fibroblasts surrounding vessels, vascular smooth muscle cells, and synovial lining cells (6, 36, 37) . In human RA, VEGF-A is detected in both synovial fluid and serum (35, 37) . The VEGF-A expression level in synovial fluid and tissues shows correlation with the clinical severity of human RA and with the degree of joint destruction (35, 36) . Among other anti-rheumatic drugs, TNF-α inhibitors are widely used, and VEGF-A inhibitors have therapeutic potential as well (6, 35, 37 Valpha is an effective therapeutic agent for treatment of retinopathy and psoriasis.
EXPERIMENTAL PROCEDURES

Generation of Recombinant Proteins
Gene constructs encoding the human TNFR2
(amino acid residues 23-257), human VEGFR1 See SI Text for more information.
RESULTS
Generation of Valpha
We designed and generated a novel fusion protein (Fig. 1C) . While the theoretical pI value of Valpha is 7.14, its actual pI value is roughly 5.5
( Fig. 1D) .
In vitro characterization of Valpha
In (Fig. 6C) . However, the number of F4/80 + macrophages (white arrow heads) was similar in VEGF-Trap-or Enbreltreated group compared to the Fc-treated group, whereas the number is significantly reduced only in Valpha-treated group (Fig. 6D) . In addition,
Valpha exerted a higher effect than combined treatment of VEGF-Trap and Enbrel in the reduction of F4/80 + macrophages infiltration to the retina of OIR (Fig. S1 ).
Valpha Shows Relieving Effects in a Psoriasis
Model by Normalizing Epidermal Thickness and Vasculature Abnormalities
As VEGF-A and TNF-α play major roles in the pathogenesis of psoriasis, we applied Valpha on the psoriasis model using K14-VEGF-A transgenic mice. The previously described protocol (33, 34) was slightly modified by challenging the sustained stimuli even during the protein treatment in order to maintain chronic inflammation, which is more clinically relevant than the protocol used earlier.
TPA (0.02 %) was applied during the protein treatment together with an injection of each protein following the first 2-week induction period (Fig. 7A) . (Fig. 7E) .
Furthermore, according to the quantification analysis of immunostaining results, Valpha significantly reduced the area of blood vessels as well as that of lymphatic vessels which are known to be implicated in the pathogenesis of psoriasis (Fig. 7 F and G) . Moreover, Valpha exerted greater anti-edema and anti-angiogenic activities than combined therapy of VEGF-Trap and Enbrel in the psoriasis mouse model (Fig. S2) .
Valpha Shows Similar Level of Therapeutic Effects with Other Single Inhibitors in an Arthritis Model
Rheumatoid arthritis (RA) is the most common inflammatory arthritis and suppression of angiogenesis may provide benefits in RA (35, 36) .
We generated collagen induced arthritis (CIA) models and tested the effect of Fc, VEGF-Trap, Enbrel, and Valpha in mice. Fc-treated group developed severe swelling and erythema, whereas the mice treated with VEGF-Trap, Enbrel, or
Valpha developed mild swelling and erythema in their hind paws (Fig. S3A) . The CIA severity can be determined using a clinical arthritis score and measurements of hind paw thickness. All parameters for the clinical course of CIA indicated that arthritis was significantly attenuated with VEGF-Trap, Enbrel, or Valpha treatments compared with Fc ( Fig. S3 B and C) . However, the degree of anti-arthritic effect of Valpha was just as similar to that of VEGF-Trap or Enbrel for the clinical arthritis score and hind paw thickness (Fig. S3 B and C) .
DISCUSSION
In this study, we developed a novel chimeric The gels were stained with Coomassie blue. A bracket marks the pI range of the Valpha protein.
Reference pI values are indicated at left. 
